المؤلفون: Steve Chan, Andrew M Wardley, Maureen E. Trudeau, L. Gianni, Maggie Liosatos, Kurt Miller, Ian E. Krop, J Sugg, M.T. Huizing, Joyce Steinberg, Louise Provencher, J. Cortes, VE Paton, Amy C. Peterson

المصدر: Cancer Research. 77:P4-22

مصطلحات موضوعية: 0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, Population, Phases of clinical research, 03 medical and health sciences, Prostate cancer, chemistry.chemical_compound, 0302 clinical medicine, Breast cancer, Trastuzumab, Internal medicine, medicine, Enzalutamide, education, education.field_of_study, business.industry, Cancer, Evaluable Disease, medicine.disease, 030104 developmental biology, chemistry, 030220 oncology & carcinogenesis, business, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::f4b048c03d4a5bf9090c28c45721f15a
https://doi.org/10.1158/1538-7445.sabcs16-p4-22-08

المؤلفون: Denise A. Yardley, Ian E. Krop, William J. Gradishar, Michael A. Danso, TA Traina, Steve Chan, Foluso O. Ademuyiwa, N Martinez-Janez, Vandana G. Abramson, Joel S. Parker, Clifford A. Hudis, Kathy D. Miller, Iulia Cristina Tudor, Rita Nanda, Laura García-Estévez, Joyce Steinberg, VE Paton, Karen A. Gelmon, L Ma, John Crown, Hirdesh Uppal, Janice F. Eakle, Lee S. Schwartzberg

المصدر: Cancer Research. 76:P3-07

مصطلحات موضوعية: 0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, business.industry, Phases of clinical research, Cancer, medicine.disease, 03 medical and health sciences, chemistry.chemical_compound, 030104 developmental biology, 0302 clinical medicine, Breast cancer, chemistry, 030220 oncology & carcinogenesis, Internal medicine, medicine, Adjuvant therapy, Enzalutamide, In patient, business, Clin oncol, Triple-negative breast cancer

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::1a0440ba92b297b2d0e0214cf21c9378
https://doi.org/10.1158/1538-7445.sabcs15-p3-07-25

المؤلفون: VE Paton, AA Protter, K Yoon, Hirdesh Uppal, S Noonberg, Iulia Cristina Tudor, Amy C. Peterson, VT Phan, Joel S. Parker

المصدر: Cancer Research. 76:P2-07

مصطلحات موضوعية: Cancer Research, business.industry, medicine.medical_treatment, Cancer, Gene signature, Bioinformatics, medicine.disease, Androgen receptor, chemistry.chemical_compound, Breast cancer, Oncology, Paclitaxel, chemistry, Cancer research, Medicine, Enzalutamide, business, Neoadjuvant therapy, Triple-negative breast cancer

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::a4f1fd5078c1c21375e1b3711d49f917
https://doi.org/10.1158/1538-7445.sabcs15-p2-07-04

المؤلفون: A Peterson, T Ervin, Véronique Diéras, M Campone, VE Paton, Q Xia, Wei Yu, BR Daniel

المصدر: Cancer Research. 71:OT3-01

مصطلحات موضوعية: Oncology, Cancer Research, medicine.medical_specialty, Bevacizumab, business.industry, Placebo-controlled study, Cancer, Phases of clinical research, medicine.disease, Metastatic breast cancer, Breast cancer, Internal medicine, Clinical endpoint, Medicine, Erlotinib, business, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::97b3a5535bba2d99cc7d0d5c11390aa1
https://doi.org/10.1158/0008-5472.sabcs11-ot3-01-11

المؤلفون: Spigel DR; David R. Spigel, Sarah Cannon Research Institute, Nashville, TN; Martin J. Edelman, University of Maryland Greenebaum Cancer Center, Baltimore, MD; Kenneth O'Byrne, Queensland University of Technology, Brisbane, Queensland, Australia; Luis Paz-Ares, Hospital Universitario Doce de Octubre and Centro Nacional de Investigaciones Oncológicas, Madrid, Spain; Simonetta Mocci, See Phan, David S. Shames, Dustin Smith, Wei Yu, and Virginia E. Paton, Genentech, South San Francisco, CA; and Tony Mok, Chinese University of Hong Kong, Hong Kong, Special Administrative Region, People's Republic of China., Edelman MJ; David R. Spigel, Sarah Cannon Research Institute, Nashville, TN; Martin J. Edelman, University of Maryland Greenebaum Cancer Center, Baltimore, MD; Kenneth O'Byrne, Queensland University of Technology, Brisbane, Queensland, Australia; Luis Paz-Ares, Hospital Universitario Doce de Octubre and Centro Nacional de Investigaciones Oncológicas, Madrid, Spain; Simonetta Mocci, See Phan, David S. Shames, Dustin Smith, Wei Yu, and Virginia E. Paton, Genentech, South San Francisco, CA; and Tony Mok, Chinese University of Hong Kong, Hong Kong, Special Administrative Region, People's Republic of China., O'Byrne K; David R. Spigel, Sarah Cannon Research Institute, Nashville, TN; Martin J. Edelman, University of Maryland Greenebaum Cancer Center, Baltimore, MD; Kenneth O'Byrne, Queensland University of Technology, Brisbane, Queensland, Australia; Luis Paz-Ares, Hospital Universitario Doce de Octubre and Centro Nacional de Investigaciones Oncológicas, Madrid, Spain; Simonetta Mocci, See Phan, David S. Shames, Dustin Smith, Wei Yu, and Virginia E. Paton, Genentech, South San Francisco, CA; and Tony Mok, Chinese University of Hong Kong, Hong Kong, Special Administrative Region, People's Republic of China., Paz-Ares L; David R. Spigel, Sarah Cannon Research Institute, Nashville, TN; Martin J. Edelman, University of Maryland Greenebaum Cancer Center, Baltimore, MD; Kenneth O'Byrne, Queensland University of Technology, Brisbane, Queensland, Australia; Luis Paz-Ares, Hospital Universitario Doce de Octubre and Centro Nacional de Investigaciones Oncológicas, Madrid, Spain; Simonetta Mocci, See Phan, David S. Shames, Dustin Smith, Wei Yu, and Virginia E. Paton, Genentech, South San Francisco, CA; and Tony Mok, Chinese University of Hong Kong, Hong Kong, Special Administrative Region, People's Republic of China., Mocci S; David R. Spigel, Sarah Cannon Research Institute, Nashville, TN; Martin J. Edelman, University of Maryland Greenebaum Cancer Center, Baltimore, MD; Kenneth O'Byrne, Queensland University of Technology, Brisbane, Queensland, Australia; Luis Paz-Ares, Hospital Universitario Doce de Octubre and Centro Nacional de Investigaciones Oncológicas, Madrid, Spain; Simonetta Mocci, See Phan, David S. Shames, Dustin Smith, Wei Yu, and Virginia E. Paton, Genentech, South San Francisco, CA; and Tony Mok, Chinese University of Hong Kong, Hong Kong, Special Administrative Region, People's Republic of China., Phan S; David R. Spigel, Sarah Cannon Research Institute, Nashville, TN; Martin J. Edelman, University of Maryland Greenebaum Cancer Center, Baltimore, MD; Kenneth O'Byrne, Queensland University of Technology, Brisbane, Queensland, Australia; Luis Paz-Ares, Hospital Universitario Doce de Octubre and Centro Nacional de Investigaciones Oncológicas, Madrid, Spain; Simonetta Mocci, See Phan, David S. Shames, Dustin Smith, Wei Yu, and Virginia E. Paton, Genentech, South San Francisco, CA; and Tony Mok, Chinese University of Hong Kong, Hong Kong, Special Administrative Region, People's Republic of China., Shames DS; David R. Spigel, Sarah Cannon Research Institute, Nashville, TN; Martin J. Edelman, University of Maryland Greenebaum Cancer Center, Baltimore, MD; Kenneth O'Byrne, Queensland University of Technology, Brisbane, Queensland, Australia; Luis Paz-Ares, Hospital Universitario Doce de Octubre and Centro Nacional de Investigaciones Oncológicas, Madrid, Spain; Simonetta Mocci, See Phan, David S. Shames, Dustin Smith, Wei Yu, and Virginia E. Paton, Genentech, South San Francisco, CA; and Tony Mok, Chinese University of Hong Kong, Hong Kong, Special Administrative Region, People's Republic of China., Smith D; David R. Spigel, Sarah Cannon Research Institute, Nashville, TN; Martin J. Edelman, University of Maryland Greenebaum Cancer Center, Baltimore, MD; Kenneth O'Byrne, Queensland University of Technology, Brisbane, Queensland, Australia; Luis Paz-Ares, Hospital Universitario Doce de Octubre and Centro Nacional de Investigaciones Oncológicas, Madrid, Spain; Simonetta Mocci, See Phan, David S. Shames, Dustin Smith, Wei Yu, and Virginia E. Paton, Genentech, South San Francisco, CA; and Tony Mok, Chinese University of Hong Kong, Hong Kong, Special Administrative Region, People's Republic of China., Yu W; David R. Spigel, Sarah Cannon Research Institute, Nashville, TN; Martin J. Edelman, University of Maryland Greenebaum Cancer Center, Baltimore, MD; Kenneth O'Byrne, Queensland University of Technology, Brisbane, Queensland, Australia; Luis Paz-Ares, Hospital Universitario Doce de Octubre and Centro Nacional de Investigaciones Oncológicas, Madrid, Spain; Simonetta Mocci, See Phan, David S. Shames, Dustin Smith, Wei Yu, and Virginia E. Paton, Genentech, South San Francisco, CA; and Tony Mok, Chinese University of Hong Kong, Hong Kong, Special Administrative Region, People's Republic of China., Paton VE; David R. Spigel, Sarah Cannon Research Institute, Nashville, TN; Martin J. Edelman, University of Maryland Greenebaum Cancer Center, Baltimore, MD; Kenneth O'Byrne, Queensland University of Technology, Brisbane, Queensland, Australia; Luis Paz-Ares, Hospital Universitario Doce de Octubre and Centro Nacional de Investigaciones Oncológicas, Madrid, Spain; Simonetta Mocci, See Phan, David S. Shames, Dustin Smith, Wei Yu, and Virginia E. Paton, Genentech, South San Francisco, CA; and Tony Mok, Chinese University of Hong Kong, Hong Kong, Special Administrative Region, People's Republic of China., Mok T; David R. Spigel, Sarah Cannon Research Institute, Nashville, TN; Martin J. Edelman, University of Maryland Greenebaum Cancer Center, Baltimore, MD; Kenneth O'Byrne, Queensland University of Technology, Brisbane, Queensland, Australia; Luis Paz-Ares, Hospital Universitario Doce de Octubre and Centro Nacional de Investigaciones Oncológicas, Madrid, Spain; Simonetta Mocci, See Phan, David S. Shames, Dustin Smith, Wei Yu, and Virginia E. Paton, Genentech, South San Francisco, CA; and Tony Mok, Chinese University of Hong Kong, Hong Kong, Special Administrative Region, People's Republic of China.

المصدر: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2017 Feb; Vol. 35 (4), pp. 412-420. Date of Electronic Publication: 2016 Dec 12.

نوع المنشور: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial

بيانات الدورية: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Carcinoma, Non-Small-Cell Lung/*drug therapy , Erlotinib Hydrochloride/*therapeutic use , Lung Neoplasms/*drug therapy, Administration, Intravenous ; Administration, Oral ; Adult ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal/administration & dosage ; Antibodies, Monoclonal/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Carcinoma, Non-Small-Cell Lung/pathology ; Disease-Free Survival ; Drug Administration Schedule ; Erlotinib Hydrochloride/administration & dosage ; Erlotinib Hydrochloride/adverse effects ; Female ; Humans ; Kaplan-Meier Estimate ; Lung Neoplasms/pathology ; Male ; Middle Aged ; Neoplasm Staging ; Protein Kinase Inhibitors/administration & dosage ; Protein Kinase Inhibitors/adverse effects ; Protein Kinase Inhibitors/therapeutic use ; Young Adult

المؤلفون: White D; Division of Hematology, Queen Elizabeth II Health Sciences Center, Halifax, Nova Scotia, Canada. d.white@dal.ca, Kassim A, Bhaskar B, Yi J, Wamstad K, Paton VE

المصدر: Cancer [Cancer] 2013 Jan 15; Vol. 119 (2), pp. 339-47. Date of Electronic Publication: 2012 Jul 18.

نوع المنشور: Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Wiley Country of Publication: United States NLM ID: 0374236 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0142 (Electronic) Linking ISSN: 0008543X NLM ISO Abbreviation: Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Multiple Myeloma/*drug therapy , Neoplasm Recurrence, Local/*drug therapy, Aged ; Aged, 80 and over ; Antibodies, Monoclonal, Humanized/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Bevacizumab ; Boronic Acids/administration & dosage ; Bortezomib ; Disease-Free Survival ; Drug Resistance, Neoplasm ; Female ; Humans ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Multiple Myeloma/mortality ; Multiple Myeloma/pathology ; Neoplasm Recurrence, Local/mortality ; Neoplasm Recurrence, Local/pathology ; Proportional Hazards Models ; Pyrazines/administration & dosage ; Treatment Outcome

المؤلفون: Pope WB; Department of Radiologic Sciences, David Geffen School of Medicine, University of California Los Angeles, 10833 Le Conte Ave, CHS, BL-428, Los Angeles, CA 90095-1721, USA. wpope@mednet.ucla.edu, Xia Q, Paton VE, Das A, Hambleton J, Kim HJ, Huo J, Brown MS, Goldin J, Cloughesy T

المصدر: Neurology [Neurology] 2011 Feb 01; Vol. 76 (5), pp. 432-7.

نوع المنشور: Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 0401060 Publication Model: Print Cited Medium: Internet ISSN: 1526-632X (Electronic) Linking ISSN: 00283878 NLM ISO Abbreviation: Neurology Subsets: MEDLINE

مواضيع طبية MeSH: Brain Neoplasms/*drug therapy , Glioblastoma/*drug therapy , Neoplasm Recurrence, Local/*drug therapy, Antibodies, Monoclonal/administration & dosage ; Antibodies, Monoclonal/adverse effects ; Antibodies, Monoclonal, Humanized ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Bevacizumab ; Brain Neoplasms/blood supply ; Brain Neoplasms/pathology ; Camptothecin/administration & dosage ; Camptothecin/analogs & derivatives ; Disease Progression ; Female ; Glioblastoma/blood supply ; Glioblastoma/pathology ; Humans ; Irinotecan ; Male ; Middle Aged ; Neoplasm Recurrence, Local/blood supply ; Neoplasm Recurrence, Local/pathology

المؤلفون: Brufsky A; Pittsburgh Cancer Institute, Pittsburgh, PA, USA., Lembersky B, Schiffman K, Lieberman G, Paton VE

المصدر: Clinical breast cancer [Clin Breast Cancer] 2005 Aug; Vol. 6 (3), pp. 247-52.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 100898731 Publication Model: Print Cited Medium: Print ISSN: 1526-8209 (Print) Linking ISSN: 15268209 NLM ISO Abbreviation: Clin Breast Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Antibodies, Monoclonal/*therapeutic use , Antineoplastic Agents/*therapeutic use , Breast Neoplasms/*drug therapy , Breast Neoplasms/*metabolism , Receptors, Steroid/*biosynthesis, Antibodies, Monoclonal, Humanized ; Breast Neoplasms/genetics ; Breast Neoplasms/pathology ; Clinical Trials as Topic ; Female ; Genes, erbB-2/physiology ; Humans ; Neoplasm Metastasis ; Neoplasm Staging ; Retrospective Studies ; Survival Analysis ; Trastuzumab ; Treatment Outcome

المؤلفون: Vadhan-Raj S; University of Texas M.D. Anderson Cancer Center, Houston, USA., Murray LJ, Bueso-Ramos C, Patel S, Reddy SP, Hoots WK, Johnston T, Papadopolous NE, Hittelman WN, Johnston DA, Yang TA, Paton VE, Cohen RL, Hellmann SD, Benjamin RS, Broxmeyer HE

المصدر: Annals of internal medicine [Ann Intern Med] 1997 May 01; Vol. 126 (9), pp. 673-81.

نوع المنشور: Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.

بيانات الدورية: Publisher: American College of Physicians--American Society of Internal Medicine Country of Publication: United States NLM ID: 0372351 Publication Model: Print Cited Medium: Print ISSN: 0003-4819 (Print) Linking ISSN: 00034819 NLM ISO Abbreviation: Ann Intern Med Subsets: MEDLINE

مواضيع طبية MeSH: Blood Platelets/*metabolism , Megakaryocytes/*metabolism , Neoplasms/*blood , Thrombocytopenia/*prevention & control , Thrombopoietin/*administration & dosage, Antibodies/blood ; Antineoplastic Agents/adverse effects ; Blood Platelets/drug effects ; Bone Marrow/drug effects ; Hematopoiesis/drug effects ; Humans ; Injections, Intravenous ; Megakaryocytes/drug effects ; Neoplasms/drug therapy ; Platelet Count/drug effects ; Ploidies ; Recombinant Proteins/administration & dosage ; Recombinant Proteins/pharmacokinetics ; Thrombocytopenia/chemically induced ; Thrombopoietin/pharmacokinetics